Study of Hepalatide in Chronic Hepatitis D(CHD) Patients

Shanghai HEP Pharmaceutical

Status and phase: Completed; Phase 2

Conditions: Chronic Hepatitis D Infection

Treatments: Drug: Hepalatide; Drug: Hepalatide Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT05827146

L47-HD-IIa

Details and patient eligibility

About

A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D

Full description

This is a four-arm parallel-group, randomized, placebo-controlled, double-blind, multicenter Phase IIa clinical trial. The CHD subjects who meet the eligibility criteria will be randomly assigned 1:1:1:1 to receive either the placebo or investigational drug (2.1 mg, 4.2 mg, or 6.3 mg), with 6 subjects per group . The placebo or the corresponding dose of the investigational drug will be given for 4 consecutive weeks, followed by a 4-week follow-up period. Subjects will be given entecavir for the treatment of hepatitis B infection during and after the end of the trial.

Enrollment: 23 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, 18-65 years old (both inclusive);
• HBsAg (+) and/or HBV DNA (+) for at least 6 months (clinically diagnosed as "chronic hepatitis B");
• HDV-antibody (IgG/IgM) (+) and HDV RNA (+);
• 1×ULN <ALT<10×ULN；
• Patients with hepatitis B eligible to receive treatment with NAs according to current guidelines for the diagnosis and treatment of hepatitis B;
• Patients who do not plan a pregnancy within two years (women who are not pregnant or lactating) and agree to take effective contraceptive measures throughout the treatment period and within 3 months after the last dose;
• Patients who did not participate in any other clinical trials within 3 months;
• Patients with good compliance with the study protocol;
• Patients who understand and agree to sign an informed consent form.

Exclusion criteria

• Decompensated liver disease: Direct bilirubin > 1.2× ULN, prothrombin time > 1.2× ULN, and serum albumin < 35 g/L;

• Patients with abnormal results of routine hematology test: White blood cell count (WBC) < 3×109/L, neutrophil count < 1.5×109/L and platelet count < 60×109/L;

• Severely decompensated hepatic fiborosis or decompensated cirrhosis: Definitely diagnosed decompensated cirrhosis by imaging examinations such as a Color Doppler ultrasound and CT of the abdomen or clinically diagnosed decompensated cirrhosis by the investigator, or a Metavir fibrosis score of 4 on a liver biopsy sample, or a Child-Pugh score > 7 for liver function assessment;

• Patients who have any of the following conditions:

  1. A history of decompensated liver disease (ascites, jaundice, hepatic encephalopathy, variceal bleeding);
  2. A history of serious cardiovascular disease (including unstable or uncontrolled cardiovascular disease within 6 months);
  3. Serious mental illness or a history of serious mental illness;
  4. A history of organ transplantation;
  5. Uncontrolled epilepsy, mental illness, or poorly controlled diabetes or hypertension;
  6. Autoimmune disease, immune-related extrahepatic manifestations (vasculitis, purpura, arteritis nodosa, peripheral neuropathy, and glomerulonephritis), thyroid disease, malignant tumor, and receiving immunosuppressive therapy;
  7. Underlying diseases such as severe infection, heart failure, chronic obstructive pulmonary disease, and other severe diseases;
  8. A history of alcohol or drug abuse.

• Creatinine clearance < 60 mL/min;

• HAV/HCV/HEV/HIV co-infection;

• Resistance to or poor response to Entecavir;

• An allergic reaction to Entecavir;

• Patients who have used interferon within 3 months before the screening period;

• Previously received L47 or Bulevirtide;

• Women who have a positive pregnancy test;

• Patients who have other significantly abnormal results of laboratory or auxiliary tests and are unsuitable for this trial.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

23 participants in 4 patient groups, including a placebo group

Hepalatide 2.1mg

Experimental group

Description:

2.1 mg/day subcutaneously (s.c.) for 4 week

Treatment:

Drug: Hepalatide

Hepalatide 4.2mg

Experimental group

Description:

4.2 mg/day subcutaneously (s.c.) for 4 week

Treatment:

Drug: Hepalatide

Hepalatide 6.3mg

Experimental group

Description:

6.3 mg/day subcutaneously (s.c.) for 4 week

Treatment:

Drug: Hepalatide

Placebo 2.1mg/4.2mg/6.3mg

Placebo Comparator group

Description:

Placebo 2.1 mg/4.2mg/6.3mg, once a day subcutaneously (s.c.) for 4 week

Treatment:

Drug: Hepalatide Placebo